Nicola Coppola; Ivan Gentile; Giuseppe Pasquale; Antonio Riccardo Buonomo; Nicolina Capoluongo; Maria D’Armiento; Guglielmo Borgia; Evangelista Sagnelli

Severe Vitamin D Deficiency Increases Mortality Among Patients With Liver Cirrhosis Regardless of the Presence of HCC

In Vivo 33(1) (2018)

ANTONIO RICCARDO BUONOMO; RICCARDO SCOTTO; EMANUELA ZAPPULO; MARIAGIOVANNA NERILLI; BIAGIO PINCHERA; GIUSEPPE PERRUOLO; PIETRO FORMISANO; SALVATORE NAPPA; IVAN GENTILE

The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C

Expert Opinion on Drug Discovery 10(12) (2015)

Ivan Gentile; Alberto Enrico Maraolo; Antonio Riccardo Buonomo; Emanuela Zappulo; Guglielmo Borgia

Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection

Reviews on Recent Clinical Trials 9(2) (2014)

Ivan Gentile; Antonio Buonomo; Guglielmo Borgia

Efficacy and Safety of Sofosbuvir in the Treatment of Chronic Hepatitis C: The Dawn of a New Era

Reviews on Recent Clinical Trials 9(1) (2014)

Ivan Gentile; Federico Borgia; Emanuela Zappulo; Antonio Buonomo; Anna Spera; Giuseppe Castaldo; Guglielmo Borgia

Understanding the Complexities of Cirrhosis

Clinical Therapeutics 37(8) (2015)

Andrew J. Muir

Hepatic flares in chronic hepatitis C: Spontaneous exacerbation vs hepatotropic viruses superinfection

World Journal of Gastroenterology 20(22) (2014)

Evangelista Sagnelli

New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir

Expert Review of Clinical Pharmacology 9(2) (2016)

Sean M. McConachie; Sheila M. Wilhelm; Pramodini B. Kale-Pradhan

ABT-450: A Novel Protease Inhibitor for the Treatment of Hepatitis C Virus Infection

Current Medicinal Chemistry 21(28) (2014)

Ivan Gentile; Federico Borgia; Antonio Buonomo; Emanuela Zappulo; Giuseppe Castaldo; Guglielmo Borgia

Daclatasvir: The First of a New Class of Drugs Targeted Against Hepatitis C Virus NS5A

Current Medicinal Chemistry 21(12) (2014)

I. Gentile; F. Borgia; N. Coppola; A.R. Buonomo; G. Castaldo; G. Borgia

Metavir and FIB-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma: a retrospective cohort study at two centers in China

Oncotarget 8(1) (2016)

Rui Liao; Yi-Peng Fu; Ting Wang; Zhi-Gang Deng; De-Wei Li; Jia Fan; Jian Zhou; Gen-Sheng Feng; Shuang-Jian Qiu; Cheng-You Du

Ferritin and liver fibrosis among patients with chronic hepatitis C virus infection

Journal of Trace Elements in Medicine and Biology 61 (2020)

Candelaria Martín-González; Ricardo Pelazas-González; Camino Fernández-Rodríguez; Remedios Alemán-Valls; Antonio Martínez-Riera; Paula Ortega-Toledo; Alen García-Rodríguez; Melchor Rodríguez-Gaspar; Emilio González-Reimers

Development and Validation of a Noninvasive Risk Score Model for Liver Cirrhosis in At-Risk Alcohol Drinkers Without HBV/HCV Infection

Cancer Prevention Research 15(11) (2022)

Yin Liu; Lan-Wei Guo; Hui-Fang Xu; Rui-Hua Kang; Li-Yang Zheng; Lu-Yao Zhang; Qiong Chen; Xi-Bin Sun; You-Lin Qiao; Shao-Kai Zhang

Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development

Expert Opinion on Investigational Drugs 25(5) (2016)

Ivan Gentile; Riccardo Scotto; Emanuela Zappulo; Antonio Riccardo Buonomo; Biagio Pinchera; Guglielmo Borgia

Beclabuvir for the treatment of hepatitis C

Expert Opinion on Investigational Drugs 24(8) (2015)

Ivan Gentile; Emanuela Zappulo; Antonio Riccardo Buonomo; Alberto Enrico Maraolo; Guglielmo Borgia

Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis

Expert Opinion on Investigational Drugs 24(9) (2015)

Jerzy Jaroszewicz; Marta Flisiak-Jackiewicz; Dariusz Lebensztejn; Robert Flisiak

Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus

Expert Opinion on Investigational Drugs 23(9) (2014)

Ivan Gentile; Nicola Coppola; Antonio Riccardo Buonomo; Emanuela Zappulo; Guglielmo Borgia

MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection

Expert Opinion on Investigational Drugs 23(5) (2014)

Ivan Gentile; Antonio Riccardo Buonomo; Federico Borgia; Emanuela Zappulo; Giuseppe Castaldo; Guglielmo Borgia

Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection

Expert Opinion on Investigational Drugs 23(4) (2014)

Ivan Gentile; Antonio Riccardo Buonomo; Federico Borgia; Giuseppe Castaldo; Guglielmo Borgia

Noninvasive scoring algorithm to identify significant liver fibrosis among treatment-naive chronic hepatitis C patients

European Journal of Gastroenterology & Hepatology 26(10) (2014)

Tomas Koller; Jana Kollerova; Martin Huorka; Iveta Meciarova; Juraj Payer

Risk of Liver Cirrhosis in At-Risk Alcohol Drinkers Without HBV/HCV Infection: Development and Validation of a Simple Non-Invasive Risk Score Model

SSRN Electronic Journal (2021)

Yin Liu; Lan-wei Guo; Hui-fang Xu; Rui-hua Kang; Li-yang Zheng; Lu-yao Zhang; Qiong Chen; Xi-bin Sun; Shao-kai Zhang; You-Lin Qiao

Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection

Therapeutics and Clinical Risk Management (2014)

Ivan Gentile; Antonio Riccardo Buonomo; Emanuela Zappulo; Giuseppina Minei; Filomena Morisco; Francesco Borrelli; Nicola Coppola; Guglielmo Borgia